NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

In the first study to be performed under the terms of the partnership, BGI will sequence 250 cancer cell lines using next-generation whole-exome sequencing. It and H3 Biomedicine will jointly analyze the data and then deliver a highly curated set of "genetically profiled, pre-clinical model information that will help to accelerate drug discovery and development efforts."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.